XW0H7K8
Introduction Lower GI to New Technology Group 8 with Sabizabulin, Via Natural or Artificial Opening Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | H Lower GI |
| Approach | 7 Via Natural or Artificial Opening |
| Device | K Sabizabulin |
| Qualifier | 8 New Technology Group 8 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Lower GI
The lower gastrointestinal tract, comprising the jejunum, ileum, colon, and rectum, is the target for Introduction procedures under New Technology when a novel agent is instilled directly into this portion of the bowel, often via colonoscopic or rectal access. This route may be selected for substances intended to act locally on colonic or rectal mucosa, such as certain investigational therapeutics, rather than for systemic absorption. Because the lower GI tract has a longer transit time and different microbial environment than the upper tract, the pharmacokinetics and intended effect of an introduced substance can differ substantially by segment. Accurate coding depends on confirming that the substance meets New Technology criteria and was delivered specifically into the lower, rather than upper, gastrointestinal tract.
Approach: Via Natural or Artificial Opening
This approach accesses the target site through an existing body orifice or a previously created artificial opening without endoscopic visualization. It differs from the endoscopic version by omitting a scope, and from percutaneous approaches by relying on a natural or surgically established passage rather than puncturing the skin.
Device / Substance / Technology: Sabizabulin
This value captures administration of sabizabulin, an oral microtubule disruption agent studied for treatment of severe COVID-19 to reduce inflammation-driven lung injury and mortality risk in hospitalized patients. Its antiviral-adjacent, anti-inflammatory mechanism differs from direct antivirals or immune-based therapies, placing it among a set of pandemic-era New Technology agents alongside baricitinib that target host response rather than the pathogen itself.
Qualifier: New Technology Group 8
Group 8 identifies technologies added to the New Technology section for the 2021-2022 update cycle, tying a given code to that specific approval year. The underlying substance, device, or technique is defined by the other six axis positions, not by the group number itself. Because group numbers simply track chronology, Group 8 differs from Group 7 and Group 9 only in when CMS granted the technology separate recognition.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.